Additional research has indicated that these immunodominant epitopes appear to be equally accessible in both tumors and normal cells, raising concerns that Trop2-directed mAbs targeting these epitopes may cause unmanageable off-tumor toxicity 6, 53, 55. Here, TACSTD2 is linked to neoplasm.